Chemical Synthesis of Lipid Mediator 22-HDoHE and Structural Analogs
- 技術優勢
- Anti-angiogenic and anti-tumor activity in vitro and in vivo Potentially fewer side-effects Chemical synthesis
- 技術應用
- Inhibit tumor growth, angiogenesis, and lymphangiogenesis
- 詳細技術說明
- Although effective, current FDA approved angiogenesis inhibitors to treat angiogenic diseases, like macular degeneration, or to inhibit tumor growth in cancer have various limitations. Several of these drugs, which utilize synthetic compounds, are associated with adverse side effects such as issues with wound healing, heart and kidney function, fetal development, and reproduction. In some cases the effects can include problems with bleeding, clots in the arteries (resulting in stroke or heart attack), hypertension, and protein in the urine. Researchers at the University of California, Davis have developed a method to chemically synthesize the natural endogenous lipid mediator, 22-hydroxydocosahexaenoic acid (22-HDoHE), with demonstrated anti-angiogenic and anti-tumor activity. 22-HDoHE is an endogenous ω-hydroxylated polyunsaturated fatty acid (PUFA) produced by cytochrome P450 omega-hydroxylase enzyme. Because it occurs in many tissues such as brain, lung, kidney and liver tissue, it has demonstrated anti-angiogenic activity in primary endothelial cells and can inhibit tumor growth in vivo. In addition, 22-HDoHE is endogenously present in the human body, meaning that this compound or its structural analogs has the potential to produce less adverse side-effects.
- *Abstract
-
Researchers at the University of California, Davis have developed an efficient method to chemically synthesize the endogenous lipid mediator, 22-hydroxydocosahexaenoic acid (22-HDoHE) which can be applied to related natural mediators and analogs.
- *Principal Investigation
-
Name: Bruce Hammock
Department:
Name: Sung Hee Hwang
Department:
Name: Guodong Zhang
Department:
- 其他
-
Related Materials
Additional Technologies by these Inventors
- Improved Dioxin Detection and Measurement
- Recombinant Neurotoxin: A More Effective Insecticide
- Antibodies: Urea Herbicide Pabs
- Antibodies: Triazine Herbicide Pabs
- Antibodies: Bacillus Delta Endotoxin PAbs
- Antibodies: Bromacil Herbicide PAbs
- Novel and Specific Inhibitors of p21
- Beneficial Effects of Novel Inhibitors of Soluble Epoxide Hydrolase as Adjuvant Treatment for Cardiac Cell-Based Therapy
- Novel Neuropathy Treatment Using Soluble Epoxide Inhibitors
- Detection System for Small Molecules
- Methods and Compositions of Treating Diabetic Nephropathy and Insulin Resistance
- Method of Preventing Bone Loss and Periodontal Disease
- A New Pharmaceutical Therapy Target for Depression and Other Central Nervous System Diseases
- Multi-Target Inhibitors for Pain Treatment
- Antibodies for Pseudomonas (P.) aeruginosa
- Soluble Epoxide Hydrolase-Conditioned Stem Cells for Cardiac Cell-Based Therapy
- PTUPB Compound Potentiates Cisplatin-Based-First Line Therapies with No Additional Toxicity
- Small Molecule sEH Inhibitors to Treat Alpha-Synuclein Neurodegenerative Disorders
- Bioavailable Dual sEH/PDE4 Inhibitor for Inflammatory Pain
Tech ID/UC Case
27634/2017-111-0
Related Cases
2017-111-0
- 國家/地區
- 美國
欲了解更多信息，請點擊 這裡
